Keywords: Teva, Cephalon, Financial results, Second-quarter 2011, Executive appointments

Teva's EPS rockets, helped by higher sales in USA

Article | 03 August 2012

Print This

Israel-based Teva Pharmaceutical Industries (NYSE: TEVA), the world’s largest generic drugs producer net revenues of $5.0 billion for the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in